Exelixis (EXEL)
(Delayed Data from NSDQ)
$37.26 USD
+1.04 (2.87%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $37.26 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
Fundamental Charts
About Market Cap
As of the previous market close, Exelixis, Inc. has a market cap of $9.75B, which represents its share price of $36.22 multiplied by its outstanding shares number of 269.20M. As a mid-cap company, EXEL's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
EXEL 37.26 +1.04(2.87%)
Will EXEL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for EXEL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EXEL
Bristol Myers Beats on Q2 Earnings and Sales, Raises '25 Sales View
Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes"
EXEL: What are Zacks experts saying now?
Zacks Private Portfolio Services
2 Highly Ranked Stocks to Consider After Q2 Earnings: CLS, EXEL
All You Need to Know About Exelixis (EXEL) Rating Upgrade to Strong Buy
EXEL Q2 Earnings Top, Sales Miss on Lower Collaboration Revenues
Other News for EXEL
Exelixis: Zanzalintinib Sees Mixed Progress, Cabozantinib Grinds Upwards
Franklin Biotechnology Discovery Fund Q2 2025 Commentary
Exelixis (EXEL) Neutral Rating Maintained by UBS, Price Target Lowered | EXEL Stock News
Exelixis (EXEL) Target Price Reduced by UBS to $38
Exelixis price target lowered by $5 at UBS